全文获取类型
收费全文 | 223篇 |
免费 | 16篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
妇产科学 | 8篇 |
基础医学 | 18篇 |
口腔科学 | 7篇 |
临床医学 | 10篇 |
内科学 | 51篇 |
皮肤病学 | 4篇 |
神经病学 | 8篇 |
特种医学 | 6篇 |
外科学 | 10篇 |
综合类 | 7篇 |
预防医学 | 12篇 |
眼科学 | 17篇 |
药学 | 62篇 |
中国医学 | 2篇 |
肿瘤学 | 15篇 |
出版年
2023年 | 2篇 |
2021年 | 2篇 |
2018年 | 5篇 |
2017年 | 8篇 |
2016年 | 1篇 |
2015年 | 8篇 |
2014年 | 7篇 |
2013年 | 11篇 |
2012年 | 19篇 |
2011年 | 19篇 |
2010年 | 5篇 |
2009年 | 9篇 |
2008年 | 14篇 |
2007年 | 8篇 |
2006年 | 5篇 |
2005年 | 6篇 |
2004年 | 28篇 |
2003年 | 21篇 |
2002年 | 11篇 |
2001年 | 11篇 |
1999年 | 6篇 |
1998年 | 4篇 |
1997年 | 5篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1956年 | 1篇 |
1955年 | 1篇 |
1954年 | 2篇 |
1953年 | 1篇 |
1952年 | 2篇 |
1951年 | 1篇 |
1950年 | 1篇 |
1949年 | 1篇 |
排序方式: 共有241条查询结果,搜索用时 15 毫秒
11.
Extracts of Monascusus Purpureus beyond Statins——Profile of Efficacy and Safety of the Use of Extracts of Monascus Purpureus 下载免费PDF全文
BIANCHI Antonio 《中国结合医学杂志》2005,(4)
Monascus purpureus is a fungus that has been tradi-tionally used in China for thousands of years to produce ricewine . Traditionally the fungus is used to ferment non-gluti-nous cooking of rice ,to produce a kind of famous red ricewine .Its main traditional indications consist of disordersdue to the accumulation of fats (nosologically linked withthe problems of stasis of circulation in traditional Chinesemedicine) ,liver disorders and some forms of tumor as ithelps i mprove the circulation of … 相似文献
12.
Perri F Zagari RM Uebersax JS Quitadamo M Bazzoli F;Helicobacter Pylori Sige Study Group on ¹³CO₂ Measurement Standardization Amarri S Armuzzi A Cantoni F Colombo R De Berardinis F De Pretis G Dell'Anna L Festi D Neri M Geypens B Ierardi E Johnson P Marchi S Masoero G Micunco C Palli D Russo A Palmas F Realdi G Sangaletti O Savarino V Stellaard F Vigneri S 《Alimentary pharmacology & therapeutics》2003,17(10):1291-1297
BACKGROUND: 13C breath test analysis requires accurate 13CO2 measurements. AIM:: To perform a multicentre study to evaluate the repeatability and reproducibility of breath 13CO2 analysis. METHODS: Two series of 25 paired randomly coded tubes (each consisting of 23 13CO2-enriched breath samples and two samples of standard reference pure CO2 with certified delta 13CPDB) were sent to participating centres for 13CO2 measurement. Each series of tubes was analysed 10 days apart. The repeatability and reproducibility of 13C measurements was assessed by Mandel's k and h statistics. RESULTS: Twenty-two centres participated in the study: 18 showed good inter- and intra-laboratory variability, whilst four showed abnormally high inter- or intra-laboratory variability. Breath test results were also significantly affected by the accuracy of the 13C analytical procedures. CONCLUSIONS: A low accuracy of 13C measurements may significantly affect the results of breath tests, leading to inappropriate clinical decisions. Standardization of 13C analysis is required to guarantee optimal 13C measurements and accurate 13C breath test results. 相似文献
13.
14.
15.
16.
Maurício W Perroud Jr Helen N Honma Aristóteles S Barbeiro Simone CO Gilli Maria T Almeida José Vassallo Sara TO Saad Lair Zambon 《Journal of experimental & clinical cancer research : CR》2011,30(1):65
Background
Overall therapeutic outcomes of advanced non-small-cell lung cancer (NSCLC) are poor. The dendritic cell (DC) immunotherapy has been developed as a new strategy for the treatment of lung cancer. The purpose of this study was to evaluate the feasibility, safety and immunologic responses in use in mature, antigen-pulsed autologous DC vaccine in NSCLC patients.Methods
Five HLA-A2 patients with inoperable stage III or IV NSCLC were selected to receive two doses of 5 × 107 DC cells administered subcutaneous and intravenously two times at two week intervals. The immunologic response, safety and tolerability to the vaccine were evaluated by the lymphoproliferation assay and clinical and laboratorial evolution, respectively.Results
The dose of the vaccine has shown to be safe and well tolerated. The lymphoproliferation assay showed an improvement in the specific immune response after the immunization, with a significant response after the second dose (p = 0.005). This response was not long lasting and a tendency to reduction two weeks after the second dose of the vaccine was observed. Two patients had a survival almost twice greater than the expected average and were the only ones that expressed HER-2 and CEA together.Conclusion
Despite the small sample size, the results on the immune response, safety and tolerability, combined with the results of other studies, are encouraging to the conduction of a large clinical trial with multiples doses in patients with early lung cancer who underwent surgical treatment.Trial Registration
Current Controlled Trials: ISRCTN45563569 相似文献17.
Collin F Chêne G Retout S Peytavin G Salmon D Bouvet E Raffi F Garraffo R Mentré F Duval X;ANRS CO Aproco-Copilote Study Group 《Therapeutic drug monitoring》2007,29(2):164-170
Indinavir plasma levels are associated with antiretroviral efficacy; however, little data are available regarding toxicity. We assessed the relationship between indinavir pharmacokinetic (PK) characteristics and severe nephrolithiasis as well as other severe or serious adverse reactions. Patients included in the ANRS CO8 APROCO-COPILOTE cohort and receiving 800 mg indinavir three times daily as a first-line protease inhibitor were eligible for this study. To be included in the analysis, their plasma sample at month 1 (M1) had to be available (n = 282) to estimate using population PK modeling, indinavir PK characteristics, ie, maximum (Cmax) and trough plasma (Cres) concentrations, area under the curve (AUC), and observed/predicted concentration ratio (CR). A Cox model was used to estimate the independent effect of Cmax, Cres, AUC, and CR on the hazard of severe nephrolithiasis and serious adverse reactions. At M1, median Cmax was 6205 ng/mL, Cres 631 ng/mL, AUC 24,242 ng . h/mL, and CR 0.6. After a median follow up of 12 months, 11% of patients (30 of 282) had experienced at least one serious adverse reaction among which 12 were nephrolithiasis. In the multivariate analyses, early high indinavir Cres (ie, >/=1000 ng/mL at M1) was associated with a higher rate of severe nephrolithiasis (hazard ratio = 6.7; 95% confidence interval = 1.8-25.2; P < 0.01) and was also associated with a higher rate of all serious adverse reactions but only when nephrolithiasis were included among those cases. Prospective and early indinavir Cres determination should be recommended in the patient's care management and dosage adjustments. 相似文献
18.
19.
7-氨基头孢霉烷酸工艺研制 总被引:1,自引:0,他引:1
实验在头孢锌盐硅烷化过程中,加入了促溶剂N,N-二甲基甲酰胺,使反应周期缩短,两相反应更加充分,脱色过程采用混合炭法,增强了脱色效果。降低了7-ACA色级,从而使7-ACA质量得到了较大幅度的提高。 相似文献
20.
MYRON J. TONG SHINN-JANG HWANG MICHELLE LEFKOWITZ SHOU-DONG LEE RUTH L. CO REW CONRAD PETER SCHMID KWANG-JUEI LO 《Journal of gastroenterology and hepatology》1994,9(6):587-591
to evaluate the effect of ribavirin on serum hepatitis C virus (HCV) RNA and alanine aminotransferase (ALT) levels, 22 patients with chronic HCV infection were treated with oral ribavirin 1200 mg daily in three divided doses for 4 weeks. At the end of 4 weeks treatment, the serum ALT decreased in all but one patient and became normal in three individuals. The mean pretreatment serum ALT was reduced significantly from 193 ± 45 i.u./L to 95 ± 16 i.u./L after 4 weeks therapy (P= 0.009). However, 8 weeks after cessation of treatment, the serum ALT rose to a mean value of 154 ± 21 i.u./L. The mean pretreatment serum HCV RNA was not significantly decreased at the end of 4 weeks treatment (7.0 × 105vs 4.1 × 105 copies/mL, P > 0.05). However, serum HCV RNA levels were decreased in 12 and increased in 10 patients at the end of 4 weeks therapy. Eight weeks after cessation of therapy, the serum HCV RNA of 22 patients rose to a mean value of 4.9 ± 105 copies/mL. Six patients who continued to have elevated serum ALT and positive HCV RNA after the initial 4 weeks treatment received oral ribavirin at the same dosage for an additional 24 weeks. The serum ALT again decreased in all six patients during therapy, but rose to pretreatment values by 8 weeks after cessation of the treatment. In addition, no significant changes were noted in the mean serum HCV RNA levels during and after 24 weeks of ribavirin therapy. Our results indicate that oral ribavirin only transiently lowered serum ALT values and did not efficiently suppress HCV synthesis in patients with chronic hepatitits C infection. 相似文献